PFIZER INC Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
PFIZER INC (PFE) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $112.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2026-02-26
- PFIZER INC unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2025 was $112.00M, a 87.71% decline from fiscal 2024.
- PFIZER INC unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2024 was $911.00M, a 971.76% increase from fiscal 2023.
- PFIZER INC unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2023 was $85.00M, a 89.90% decline from fiscal 2022.
- PFIZER INC unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2022 was $842.00M, a 3408.33% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month |
|---|---|
| 2025-12-31 | $112.00M 10-K · filed 2026-02-26 |
| 2024-12-31 | $911.00M 10-K · filed 2026-02-26 |
| 2023-12-31 | $85.00M 10-K · filed 2026-02-26 |
| 2022-12-31 | $842.00M 10-K · filed 2025-02-27 |
| 2021-12-31 | $24.00M 10-K · filed 2024-02-22 |
| 2020-12-31 | $15.00M 10-K · filed 2023-02-23 |
| 2019-12-31 | $100.00M 10-K · filed 2022-02-24 |
| 2018-12-31 | $123.00M 10-K · filed 2021-02-25 |
| 2017-12-31 | $35.00M 10-K · filed 2020-02-27 |
| 2016-12-31 | $126.00M 10-K · filed 2019-02-28 |
| 2015-12-31 | $64.00M 10-K · filed 2018-02-22 |
| 2014-12-31 | $70.00M 10-K · filed 2017-02-23 |
| 2013-12-31 | $571.00M 10-K · filed 2016-02-29 |
| 2012-12-31 | $647.00M 10-K · filed 2015-02-27 |
| 2011-12-31 | $575.00M 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |